Posted: January 13, 2025 at 2:54 am
Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA
Visit link:
Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities
Posted: January 13, 2025 at 2:54 am
BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its preprint article titled “Immune Checkpoint Inhibitors (ICI): Prospects for Galectin-3 Modulation to Increase Objective Response Rate (ORR) and Remission-free Survival in Oncology Patients” (the “Article”) authored by Dr. Adesuyi Ajayi, Dr. David Platt, and Andrew Blumenthal. The preprint reviews detailed theories regarding the resistance to ICI therapy and how galectin-3 contributes to resistance.
Excerpt from:
Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs
Posted: January 13, 2025 at 2:54 am
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS
Read this article:
Virbac : Declaration of the number of shares and voti
Posted: January 13, 2025 at 2:54 am
WOBURN, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.
Read the original post:
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Posted: January 13, 2025 at 2:54 am
BEDMINSTER, N.J. , Jan. 10, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicating that the Company has fallen below certain NYSE American continued listing standards because it failed to hold its annual meeting of stockholders for the fiscal year ending on December 31, 2024, as set forth in Section 704 of the NYSE American Company Guide.
Posted: January 13, 2025 at 2:54 am
WESTLAKE VILLAGE, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced certain preliminary unaudited financial information for the fourth quarter and full-year 2024.
See the article here:
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160...
Posted: January 13, 2025 at 2:54 am
-- One year after the second vaccine dose, the anti-gE antibody immune response to amezosvatein continues to be non-inferior to Shingrix
Read the original here:
Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine
Posted: January 13, 2025 at 2:54 am
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025
Read more from the original source:
Mereo BioPharma Provides Update on Lead Clinical Programs
Posted: January 13, 2025 at 2:54 am
2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1
See original here:
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
